MX365921B - Nuevos derivados de piridina. - Google Patents

Nuevos derivados de piridina.

Info

Publication number
MX365921B
MX365921B MX2015013629A MX2015013629A MX365921B MX 365921 B MX365921 B MX 365921B MX 2015013629 A MX2015013629 A MX 2015013629A MX 2015013629 A MX2015013629 A MX 2015013629A MX 365921 B MX365921 B MX 365921B
Authority
MX
Mexico
Prior art keywords
pyridine derivatives
novel pyridine
novel
compound
formula
Prior art date
Application number
MX2015013629A
Other languages
English (en)
Spanish (es)
Other versions
MX2015013629A (es
Inventor
Schulz-Gasch Tanja
Nettekoven Matthias
Rogers-Evans Mark
Grether Uwe
Kimbara Atsushi
Roever Stephan
Rombach Didier
Gavelle Olivier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015013629A publication Critical patent/MX2015013629A/es
Publication of MX365921B publication Critical patent/MX365921B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
MX2015013629A 2013-03-26 2014-03-24 Nuevos derivados de piridina. MX365921B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13161176 2013-03-26
PCT/EP2014/055797 WO2014154612A1 (en) 2013-03-26 2014-03-24 Novel pyridine derivatives

Publications (2)

Publication Number Publication Date
MX2015013629A MX2015013629A (es) 2016-02-18
MX365921B true MX365921B (es) 2019-06-20

Family

ID=47913322

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013629A MX365921B (es) 2013-03-26 2014-03-24 Nuevos derivados de piridina.

Country Status (33)

Country Link
US (2) US10308659B2 (enExample)
EP (1) EP2978755B1 (enExample)
JP (1) JP6500010B2 (enExample)
KR (1) KR20150135458A (enExample)
CN (1) CN105121436B (enExample)
AR (1) AR095721A1 (enExample)
AU (1) AU2014243190B2 (enExample)
BR (1) BR112015024272A2 (enExample)
CA (1) CA2899168A1 (enExample)
CL (1) CL2015002835A1 (enExample)
CR (1) CR20150440A (enExample)
DK (1) DK2978755T3 (enExample)
EA (1) EA027569B1 (enExample)
ES (1) ES2661737T3 (enExample)
HR (1) HRP20180371T1 (enExample)
HU (1) HUE036934T2 (enExample)
IL (1) IL240496B (enExample)
LT (1) LT2978755T (enExample)
MA (1) MA38404B1 (enExample)
MX (1) MX365921B (enExample)
MY (1) MY174000A (enExample)
NO (1) NO2978755T3 (enExample)
PE (1) PE20151559A1 (enExample)
PH (1) PH12015501933B1 (enExample)
PL (1) PL2978755T3 (enExample)
PT (1) PT2978755T (enExample)
RS (1) RS56927B1 (enExample)
SG (1) SG11201507994QA (enExample)
SI (1) SI2978755T1 (enExample)
TW (1) TWI628174B (enExample)
UA (1) UA116239C2 (enExample)
WO (1) WO2014154612A1 (enExample)
ZA (1) ZA201505251B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2015190316A1 (ja) * 2014-06-09 2017-04-20 住友化学株式会社 ピリジン化合物の製造方法
DK3386951T3 (en) * 2015-12-09 2020-04-27 Hoffmann La Roche Phenylderivater som cannabinoidreceptor-2-agonister
KR102384529B1 (ko) * 2016-07-07 2022-04-08 코르테바 애그리사이언스 엘엘씨 4-알콕시-3-(아실 또는 알킬)옥시피콜린아미드의 제조 방법
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
JP7300398B2 (ja) * 2017-06-20 2023-06-29 エフ． ホフマン－ラ ロシュ アーゲー ピリジン誘導体
WO2019003956A1 (ja) * 2017-06-27 2019-01-03 住友化学株式会社 オキサジアゾール化合物及びその用途
CN108774220B (zh) * 2018-05-27 2019-04-23 西安培华学院 用于治疗心肌缺血的化合物及其应用
EP3995155A1 (en) 2018-06-27 2022-05-11 F. Hoffmann-La Roche AG Radiolabeled cannabinoid receptor 2 ligand
CN112074513B (zh) * 2018-06-27 2024-06-14 豪夫迈·罗氏有限公司 作为优先大麻素2激动剂的吡啶和吡嗪衍生物
BR112020025013A2 (pt) 2018-06-27 2021-03-23 F. Hoffmann-La Roche Ag novos compostos de piridina e pirazina como inibidores do receptor 2 de canabinoide
EP3814328A1 (en) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN114195759B (zh) * 2021-08-26 2023-10-20 上海零诺生物科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶制备方法
US20240425513A1 (en) * 2021-10-22 2024-12-26 Carmot Therapeutics, Inc. Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28
CN115073366B (zh) * 2022-06-08 2024-08-09 都创(重庆)医药科技有限公司 一种基于微通道技术快速制备3-氯吡啶-2-甲酸的方法
WO2025104141A1 (en) * 2023-11-16 2025-05-22 F. Hoffmann-La Roche Ag Novel reversible fluorescent probes for cb2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271266B2 (en) * 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
WO2008019357A2 (en) * 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2009051705A1 (en) * 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
KR20150027824A (ko) 2012-07-04 2015-03-12 에프. 호프만-라 로슈 아게 칸나비노이드 수용체 2 작용제로서 신규한 아다만틸 유도체
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
CA2885987A1 (en) 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
SG10201800170YA (en) 2012-12-07 2018-02-27 Hoffmann La Roche Novel pyridine derivatives
RS55951B1 (sr) 2012-12-07 2017-09-29 Hoffmann La Roche Derivati pirazina kao agonisti cb2 receptora
JP6514119B2 (ja) 2013-03-07 2019-05-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規ピラゾール誘導体
CA2943013A1 (en) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
CR20160459A (es) 2014-04-04 2016-12-02 Eidgenoessische Technische Hochschule Zuerich Nuevos derivados de piridina

Also Published As

Publication number Publication date
UA116239C2 (uk) 2018-02-26
BR112015024272A2 (pt) 2017-07-18
NO2978755T3 (enExample) 2018-06-02
ES2661737T3 (es) 2018-04-03
CR20150440A (es) 2015-10-08
KR20150135458A (ko) 2015-12-02
PH12015501933A1 (en) 2016-01-11
EP2978755A1 (en) 2016-02-03
SI2978755T1 (en) 2018-03-30
US20190248803A1 (en) 2019-08-15
SG11201507994QA (en) 2015-10-29
WO2014154612A1 (en) 2014-10-02
MX2015013629A (es) 2016-02-18
EA201591567A1 (ru) 2016-01-29
HRP20180371T1 (hr) 2018-04-06
CA2899168A1 (en) 2014-10-02
ZA201505251B (en) 2016-07-27
MA38404A1 (fr) 2017-01-31
MA38404B1 (fr) 2017-09-29
IL240496A0 (en) 2015-09-24
CN105121436A (zh) 2015-12-02
HK1211938A1 (en) 2016-06-03
PT2978755T (pt) 2018-02-26
US10308659B2 (en) 2019-06-04
AU2014243190A1 (en) 2015-07-30
HUE036934T2 (hu) 2018-08-28
LT2978755T (lt) 2018-03-12
IL240496B (en) 2019-03-31
EP2978755B1 (en) 2018-01-03
RS56927B1 (sr) 2018-05-31
CN105121436B (zh) 2018-07-27
EA027569B1 (ru) 2017-08-31
DK2978755T3 (en) 2018-03-05
TWI628174B (zh) 2018-07-01
CL2015002835A1 (es) 2016-05-20
US20160016968A1 (en) 2016-01-21
TW201518287A (zh) 2015-05-16
AR095721A1 (es) 2015-11-04
PL2978755T3 (pl) 2018-05-30
AU2014243190B2 (en) 2018-07-19
MY174000A (en) 2020-03-03
PH12015501933B1 (en) 2018-12-14
PE20151559A1 (es) 2015-11-05
JP6500010B2 (ja) 2019-04-10
JP2016516737A (ja) 2016-06-09

Similar Documents

Publication Publication Date Title
PH12015501933B1 (en) Novel pyridine derivatives
PH12015501083A1 (en) Novel pyridine derivatives
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015501073A1 (en) Novel pyridine derivatives
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MY179412A (en) Pyridine-2-amides useful as cb2 agonists
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MY180050A (en) Novel purine derivatives
MX349373B (es) Nuevos derivados de pirazina.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
MX363545B (es) Derivados piridin-4-ilo.
UA116801C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2
MX2014008918A (es) Nuevos derivados de pirrolidina.
MX363458B (es) Nuevos derivados de tetrazolona.
MX2016006807A (es) Derivados de imidazol.
PH12018501585B1 (en) Novel pyrrolidine derivatives
PH12015500262A1 (en) Novel pyridine derivatives
MX351093B (es) Nuevos derivados de azetidina.
MX2015009377A (es) Compuestos radiomarcados.
IN2013CH05884A (enExample)

Legal Events

Date Code Title Description
FG Grant or registration